{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:49:34Z","timestamp":1791244174255,"version":"4.1.0"},"reference-count":57,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.1080\/14740338.2017.1338270","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T01:40:48Z","timestamp":1503279648000},"page":"1191-1202","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":35,"title":["Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab"],"prefix":"10.1080","volume":"16","author":[{"given":"Anne C.","family":"Wilke","sequence":"first","affiliation":[{"name":"University Hospital, Department of Medicine II, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"University Hospital, Department of Medicine II, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,8,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"Loffler A","year":"2000","journal-title":"Blood"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144311"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25354"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1611445113"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1126\/science.1373518"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","volume":"131","author":"Nadler LM","year":"1983","journal-title":"J Immunol"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-379016"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.84"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"CIT0026","unstructured":"Amgen Product Characteristics [cited 2016 Dec 11]. Available from: https:\/\/fachkreise.amgen.de\/x_download.php?t=f&n=1&id=527."},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30031"},{"key":"CIT0029","unstructured":"FDA Approval of Blinatumomab. FDA. [Cited 2016 Dec 07]. Available from: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm425597.htm"},{"key":"CIT0030","unstructured":"EMA Approval of Blinatumomab. [Cited\u00a02016\u00a0Dec\u00a007].\u00a0Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003731\/human_med_001921.jsp&mid=WC0b01ac058001d124"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"CIT0032","first-page":"Abstract 379","volume-title":"American Society of Hematology (ASH) Annual Meeting","author":"G\u00f6kbuget N","year":"2014"},{"key":"CIT0033","first-page":"Abstract 680","volume-title":"American Society of Hematology (ASH) Annual Meeting","author":"G\u00f6kbuget N","year":"2015"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.239"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100073"},{"key":"CIT0037","unstructured":"Clinical trial: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (NCT02101853). [Cited\u00a02016\u00a0Dec\u00a008].\u00a0Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02101853?term=NCT02101853&rank=1"},{"key":"CIT0038","unstructured":"Clinical Trial: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (NCT02003222).[Cited\u00a02017\u00a0Feb\u00a012].\u00a0Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02003222"},{"key":"CIT0039","unstructured":"Clinical Trial: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (NCT02143414). [Cited\u00a02017\u00a0Feb\u00a012].\u00a0Available from: https:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT02143414"},{"key":"CIT0040","unstructured":"Clinical Trial: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (NCT02013167). [Cited\u00a02017\u00a0Feb\u00a012].\u00a0Available from: https:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT02013167"},{"key":"CIT0041","doi-asserted-by":"crossref","first-page":"abstr 2561","DOI":"10.1200\/jco.2015.33.15_suppl.2561","volume":"33","author":"Zhu M","year":"2015","journal-title":"J Clin Oncol"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"Feucht J","year":"2016","journal-title":"Oncotarget"},{"key":"CIT0046","first-page":"76","volume":"7","author":"Hladnik L","year":"2016","journal-title":"J Adv Pract Oncol"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2039-6"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000057830.67416.CE"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood.V116.21.2880.2880","volume":"116","author":"Viardot A","year":"2010","journal-title":"Blood"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9970"},{"key":"CIT0052","first-page":"Abstract 1589","volume-title":"American Society of Hematology (ASH) Annual Meeting","author":"Klinger M","year":"2016"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"CIT0055","unstructured":"assessed on 11-Dec-2016 http:\/\/www.akdae.de\/Arzneimittelsicherheit\/RHB\/20161025.pdf"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80010"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2017.1338270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T04:47:45Z","timestamp":1692938865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2017.1338270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,20]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["10.1080\/14740338.2017.1338270"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2017.1338270","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}